Johnson & Johnson JNJ Medtech Ortho Franchise — Restructuring
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Johnson & Johnson’s 10-K, filed February 11, 2026.
- Filed
- Feb 10, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0000200406-26-000016
(2) The fiscal year of 2025 included $152 million in restructuring, $71 million in Other income and expense and $84 million in Cost of products sold on the Consolidated Statement of Earning The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings. This program was substantially completed in the fiscal year 2025.
Item 8. Financial statements and supplementary data
FAQ
- What is Johnson & Johnson's medtech ortho franchise — restructuring?
- Johnson & Johnson (JNJ) reported medtech ortho franchise — restructuring of $38M in Q4 2025.
- How has Johnson & Johnson's medtech ortho franchise — restructuring changed year-over-year?
- Johnson & Johnson's medtech ortho franchise — restructuring increased by 15.2% year-over-year, from $33M to $38M.
- What is the long-term trend for Johnson & Johnson's medtech ortho franchise — restructuring?
- Over 2 years (2023 to 2025), Johnson & Johnson's medtech ortho franchise — restructuring has grown at a -26.2% compound annual growth rate (CAGR), from $279M to $152M.
- What does medtech ortho franchise — restructuring mean?
- This metric represents the specific costs or financial impacts associated with organizational realignment, operational streamlining, or strategic shifts within the Orthopedics business unit. It captures non-recurring expenses incurred to improve long-term margins and operational efficiency within the medical device segment. Investors monitor this to assess the magnitude of transformation efforts and the potential for future margin expansion in the orthopedic portfolio.
Ask your AI about Johnson & Johnson's medtech ortho franchise — restructuring.
Connect your AI assistant and compare segments, right in your chat.
